Epstein-Barr virus as a therapeutic target in Hodgkin's disease and nasopharyngeal carcinoma

Richard F. Ambinder, Keith D. Robertson, Stacy M. Moore, Jie Yang

Research output: Contribution to journalArticle

49 Scopus citations

Abstract

Conventional approaches to the treatment of malignancy are often not curative or are associated with serious complications. New approaches to treatment are needed. A variety of specific approaches to the destruction of virus-associated tumor cells are illustrated in the context of EBV-associated Hodgkin's disease and nasopharyngeal carcinoma. Viral antigens expressed by tumors may be targeted by cytotoxic T cells. Other viral antigens not naturally expressed by tumors may be induced by pharmacologic manipulations such as treatment with demethylating agents. Viral enzymes not naturally expressed by tumors such as thymidine kinase may be induced by protein kinase C activators, thus rendering tumor cells sensitive to Killing by ganciclovir.

Original languageEnglish (US)
Pages (from-to)217-226
Number of pages10
JournalSeminars in Cancer Biology
Volume7
Issue number4
DOIs
StatePublished - Aug 1996

Keywords

  • 5-azacytidine
  • Bryostatin
  • Epstein-barr virus
  • Hodgkin's disease
  • Nasopharyngeal carcinoma

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'Epstein-Barr virus as a therapeutic target in Hodgkin's disease and nasopharyngeal carcinoma'. Together they form a unique fingerprint.

  • Cite this